Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cellular retinoic acid-binding proteins (CRABPs) are small cytosolic proteins that function as intracellular chaperones for all-trans-retinoic acid (atRA), the primary active metabolite of vitamin A (Source: NIH). The family consists of two main isoforms, CRABP1 and CRABP2, which exhibit high affinity for atRA but serve distinct physiological roles (Source: UniProt). CRABP2 is primarily responsible for transporting atRA from the cytoplasm into the nucleus, where it facilitates the transfer of the ligand to retinoic acid receptors (RARs) to initiate gene transcription (Source: PubMed). Conversely, CRABP1 is involved in sequestering atRA and directing it toward catabolic enzymes, such as CYP26, while also participating in non-canonical signaling by modulating cytosolic kinases like CaMKII and ERK (Source: MDPI). Dysregulation of these proteins is frequently observed in various cancers, including breast and lung cancer, where they can influence tumor progression, metastasis, and sensitivity to retinoid therapy (Source: NIH). Furthermore, CRABPs have emerged as potential therapeutic targets for neurodegenerative diseases like ALS and cardiovascular conditions due to their roles in regulating cell survival and stress responses (Source: PubMed). Targeting CRABPs with selective ligands offers a promising strategy to modulate retinoid signaling while minimizing the systemic toxicity often associated with direct RAR activation (Source: MDPI).
Facilitates the intracellular transport of retinoic acid to nuclear receptors or catabolic enzymes and modulates non-canonical signaling pathways through interaction with cytosolic kinases.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cellular retinoic acid-binding protein (CRABP) (CRABP).